PTC Therapeutics Inc. Stock
PTC Therapeutics Inc. Stock
The PTC Therapeutics Inc. stock is trending slightly upwards today, with an increase of €0.20 (0.570%) compared to yesterday's price.
Currently there is a rather positive sentiment for PTC Therapeutics Inc. with 15 Buy predictions and 7 Sell predictions.
With a target price of 42 € there is a slightly positive potential of 19.32% for PTC Therapeutics Inc. compared to the current price of 35.2 €.
Our community identified positive and negative aspects for PTC Therapeutics Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the PTC Therapeutics Inc. stock. On the other hand our users think that "EBIT Margin" could be a problem in the future.
Pros and Cons of PTC Therapeutics Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of PTC Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| PTC Therapeutics Inc. | 0.570% | 24.823% | 47.899% | -34.815% | 39.683% | 12.102% | -2.547% |
| Ironwood Pharmaceuticals | 0.840% | -0.826% | -20.000% | -37.500% | -41.176% | -40.594% | - |
| Novocure Ltd | 0.090% | 13.230% | 93.040% | -70.693% | 53.485% | -85.261% | - |
| Iovance Biotherapeutics Inc. | -1.490% | -2.727% | -10.108% | 29.434% | 22.439% | -35.493% | - |
Comments
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Citigroup Inc. from $18.00 to $26.00. They now have a "sell" rating on the stock.
Show more
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at JPMorgan Chase & Co. from $43.00 to $53.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $32.00. They now have a "sell" rating on the stock.
Show more
Ratings data for PTCT provided by MarketBeat